Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lara Goldstein

A Foundational Study On Stroke Is Ready. Here Is Why It's Important

Biopharma company Algernon Pharmaceuticals Inc's (OTC:AGNPF) recently announced plan for a Phase 1 clinical study on DMT for human stroke has just received approval from the Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), an independent Medical Research Ethics Committee. 

The trial will be conducted at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands, with screening beginning shortly and dosing expected to start in the fourth quarter of 2022.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.